New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
04:55 EDTOMED, OMED, OMED, MACK, MACK, MACK, KPTI, KPTI, KPTIAmerican Gastroenterological Association to hold a symposium
2014 Gastrointestinal Cancers Symposium is being held in San Francisco on January 16-18.
News For OMED;MACK;KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
06:35 EDTOMEDOncoMed's Demcizumab shows positive Phase 1b clinical trial results
OncoMed presented new data from the Phase 1b clinical trial of demcizumab in patients with first-line advanced non-small cell lung cancer at the European Lung Cancer Conference. Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenesis and potential immune modulatory properties. Of 40 patients evaluable for efficacy, the overall RECIST response rate was 50% and an additional 15 patients had a best response of stable disease, yielding a clinical benefit rate of 88%. Median progression-free survival was 5.3 months and 5.8 months for the continuous and truncated cohorts, respectively. Prolonged PFS and OS were observed for a subset of patients treated with continuous demcizumab. A randomized Phase 2 trial of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC has been initiated and is enrolling subjects in Europe, Australia, and the United States.
April 14, 2015
09:17 EDTMACKMerrimack management to meet with Brean Capital
Subscribe for More Information
April 13, 2015
08:43 EDTKPTIKaryopharm granted U.S. composition-of-matter patent for selinexor
Karyopharm Therapeutics announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor, a first-in-class, oral SINE compound, as well as certain other compositions and related methods. Selinexor is being evaluated in multiple registration-directed and other later stage trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.
April 10, 2015
10:07 EDTMACKHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use